Concord Biotech Quarterly Results for Trading Insights
In Mar 2026, Concord Biotech (CONCORDBIO) reported revenue ₹341 Cr and net profit ₹89 Cr — revenue -22.3% YoY. Also explore CONCORDBIO price trends to track price trends across different timeframes.
CONCORDBIO Quarterly Results — Revenue, Profit & EPS Highlights
Concord Biotech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with CONCORDBIO fundamental valuation to assess whether the stock is under or overvalued.
- Revenue of ₹341 Cr in Mar 2026 (+29.7% vs Sept 2025, -22.3% vs Mar 2025)
- Net Profit of ₹89 Cr in Mar 2026 (+41.3% vs Sept 2025, -36.4% vs Mar 2025)
- EBITDA of ₹134 Cr in Mar 2026 (+28.8% vs Sept 2025)
- Operating Margin of 36.0% in Mar 2026 (+0.0pp vs Sept 2025)
- Earnings Per Share of ₹8.46 in Mar 2026 (+40.3% vs Sept 2025)
Concord Biotech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CONCORDBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 341 | 263 | 439 | 219 | 288 | 29.7% | -22.3% |
| Net Profit (₹ Cr) | 89 | 63 | 140 | 44 | 64 | - | - |
| EBITDA (₹ Cr) | 134 | 104 | 198 | 77 | 105 | - | - |
| EPS (₹) | 8.46 | 6.03 | 13.42 | 4.21 | 6.08 | - | - |
| Operating Margin (%) | 36.0% | 36.0% | 44.0% | 30.0% | 34.0% | - | - |
CONCORDBIO Share Price Trend — 1-Year Movement Across Quarterly Results
Concord Biotech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Concord Biotech share price chart.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CONCORDBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Concord Biotech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.9 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.9 |
|
Divis Laboratories
Mar 2026 |
₹175,434.91 Cr | 6787.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 239.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4457.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 387.2 |
|
Zydus Life Science
Mar 2026 |
₹109,226.70 Cr | 1085.5 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 85.8 |
|
Cipla
Mar 2026 |
₹109,195.79 Cr | 1415.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.1 |
All amounts in ₹ Crores